PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study.
Fiche publication
Date publication
juin 2019
Journal
Trials
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DUCLOUX Didier, Pr NERICH Virginie, Dr VERNEREY Dewi
Tous les auteurs :
Gaiffe E, Crepin T, Bamoulid J, Courivaud C, Büchler M, Cassuto E, Albano L, Chemouny JM, Choukroun G, Hazzan M, Kessler L, Legendre C, Le Meur Y, Ouali N, Thierry A, Anota A, Nerich V, Limat S, Bonnetain F, Vernerey D, Ducloux D
Lien Pubmed
Résumé
Post-transplant diabetes is a frequent and serious complication of kidney transplantation. There is currently no treatment to prevent or delay the disease. Nevertheless, identification of risk factors make it possible to target a population at risk of developing de novo diabetes. We hypothesized that a short-term treatment with vildagliptin may prevent new onset diabetes after transplantation (NODAT) in high-risk patients.
Mots clés
Diabetes prevention, Kidney transplantation, Randomized controlled trial, Vildagliptin
Référence
Trials. 2019 Jun 21;20(1):375